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Chronic myelogenous leukaemia (CML) is a clonal malignancy of the pluripotent haematopoietic stem cell, characterised by an
uncontrolled proliferation and expansion of myeloid progenitors expressing a fusion oncogene, BCR-ABL, the molecular counterpart
of the Ph1 chromosome. The tyrosine kinase (TK) activity of BCR-ABL is known to activate several major signalling pathways in
malignant cells, including Ras, JAK/STAT and PI3K/Akt with evidence of proteasome-mediated degradation of other targets such as
the DNA repair protein DNA-PKcs and cyclin-dependent kinases inhibitor p27. Targeting these abnormalities by blocking TK of BCR-
ABL with STI571 provided a promising approach for the therapy of CML. The recent development of resistance to STI571 illustrates,
however, that the use of other TK inhibitors could be of major interest for therapeutic purposes. To this end, the TK inhibitor
Tyrphostin AG1024 was used to evaluate effect on regulation of BCR-ABL expression, inhibition of cell proliferation and tumour
formation in vivo in human and murine BCR-ABL expressing cell lines. Tyrphostin AG1024 was shown to downregulate expression of
BCR-ABL and P-Akt, and to upregulate DNA-PKcs expression. In addition, Tyrphostin AG1024 was able to inhibit cell proliferation,
and delay tumour growth in vivo. Thus, AG1024 is able to interfere with three major targets of BCR-ABL in leukaemic cells.
Interestingly, Tyrphostin AG1024 was also effective against cells resistant to STI571 by distinct mechanisms including Bcr-Abl
mutation. Therefore, these data suggest that Tyrphostin AG1024 could represent the basis of a novel therapy for STI571 refractory
CML.
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Chronic myelogenous leukaemia (CML) is a myeloproliferative
disorder associated with the presence of the pathognomonic
Philadelphia chromosome (Ph), which is found in approximately
95% of patients. CML is a myeloproliferative disorder and it was
first described (Nowell and Hungerford, 1960) as a shortened
chromosome 22 (within the Bcr locus) and a reciprocal transloca-
tion that transfers the c-abl proto-oncogene from the chromosome
9–22 (Lugo et al, 1990; McWhirter and Wang, 1991). According to
the break within the Bcr locus (Quackenbush et al, 2000), three
oncogenic BCR-Abl fusion proteins: p190, p210 and P230 can be
formed and they all were found to be sufficient to generate
leukaemia in humans and murine models (Daley et al, 1990;
Huettner et al, 2000). Indeed, the Bcr-Abl oncogene was found to
induce a constitutive increase in the tyrosine kinase (TK) activity
(Konopka and Witte, 1985), which is sufficient for its transforming
capacity. Recent advances in CML research have highlighted the
role of the Bcr-Abl oncoprotein as a molecular abnormality that
leads to phenotypic changes in Bcr-Abl expressing cells, and
contributes to malignant transformation of cells. In fibroblasts and
haematopoietic cells transformation models, it was shown that
Bcr-Abl induces mitogenesis (Raitano et al, 1997) and growth
factor independence (Mandanas et al, 1992; Cambier et al, 1998;
Issaad et al, 2000). Studies have demonstrated that the expression
of Bcr-Abl fusion proteins protects cells from apoptosis induced by
stimuli such as cytokine withdrawal, DNA damage or Fas
activation (Bedi et al, 1994, 1995; Benito et al, 1996). By using
Bcr-Abl mutant constructs, separated signalling pathways were
found to be involved in the protection of cells from apoptosis and
in cell transformation (Cortez et al, 1995). It was reported that Bcr-
Abl activates several signalling pathways including Ras, Myc, Stat5
and PI3K/Akt (14–20). The antiapoptotic potential of Bcr-Abl was
attributed to the increase of Bcl2/BclXL induced by the activation
of Stat5 and PI3K/Akt pathways (Sanchez Garcia and Grutz, 1995;
Gesbert et al, 2000). Furthermore, we previously demonstrated that
DNA-PKcs (Deutsch et al, 2001) and BRCA1 (Deutsch et al, 2003),
two major DNA repair proteins, are downregulated by Bcr-Abl in
leukaemic cells, these downregulation processes were associated
with a major DNA repair deficiency. Thus, we hypothesised that
strong resistance to apoptosis along with the DNA repair
deficiency induced by Bcr-Abl allow the accumulation of
secondary genetic abnormalities leading to the clonal evolution
toward blast crisis.
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sBCR-ABL induces mitogenesis in fibroblasts and haematopoietic
cells (Raitano et al, 1997). BCR-ABL expression induces growth
factor independence in factor-dependent cell lines in a dose-
dependent manner (Issaad et al, 2000). During the recent years,
progresses obtained in the understanding of the BCR-ABL-induced
signalling have made possible to correlate signalling abnormalities
to phenotypic changes observed in BCR-ABL-expressing cells.
Previous studies using BCR-ABL mutant constructs suggested that
signals responsible for protection from apoptosis may be separated
from those responsible for transformation (Cortez et al, 1995).
Among the major signalling intermediates activated, there is a
clear role of RAS, MYC, STAT5, phosphatidylinositol 3-kinase/Akt
pathways for the transforming effects of Bcr-Abl (Cleveland et al,
1989; Okuda et al, 1994; Skorski et al, 1995; Ilaria and Van Etten,
1996). The use of dominant-negative constructs allowed to
determine STAT5 and PI-3K pathways to be major signalling
pathways responsible of the antiapoptotic potential of BCR-ABL
(Gesbert et al, 2000), by activation of Bcl2/BclXL (Sanchez Garcia
and Grutz, 1995). The central role of Bcr-Abl oncogene in CML
suggested Bcr-Abl to be an attractive target for leukaemia therapy.
This led to the successful development of new targeted agents such
as STI571, which inhibits the TK activity of constitutive activated
forms of Abl protein (v-Abl, p210Bcr-Abl, p185Bcr-Abl, Tel-Abl
fusion proteins) (Buchdunger et al, 1996; Druker et al, 1996;
Carroll et al, 1997). Preclinical and clinical studies have shown that
Abl TK inhibition by STI571 was efficient in both p210 Bcr-Abl-
positive and p185Bcr-Abl-positive cell lines as well as in primary
leukaemia cells obtained from patients having Ph-positive CML
and ALL (Beran et al, 1998). Further, STI571 was found to inhibit
stem cell factor (SCF)-mediated cellular events such as c-Kit
autophosphorylation and SCF-mediated activation of MAP kinase
and Akt (Buchdunger et al, 2000; Heinrich et al, 2000). Despite the
major antileukaemic effect of STI571 in chronic phase CML,
clinical resistance to STI571 treatment was observed in patients
with advanced phase diseases and was attributed to the mutations
in the ATP-binding site of the Bcr-Abl protein, which alters drug
binding and thus its inhibitory effects (La Rosee et al, 2002; Roche-
Lestienne et al, 2002). Therefore, antileukaemic strategies targeting
TK inhibition by new agents alone or in combination with STI571
need to be investigated. Bcr-Abl has been shown to be
leukaemogenic in a variety of animal models (Daley et al, 1990)
essentially by its deregulated TK activity (Lugo et al, 1990). PI3K
and Akt have been linked to enhanced cell survival through the
phosphorylation and subsequent inhibition of the proapoptotic
molecule Bad (Neshat et al, 2000). Bcr-Abl regulates the expression
of p27Kip1 in a proteasome-dependent manner and through
activation of PI3K and Akt (Gesbert et al, 2000). Tyrphostin
AG1024 has been reported to induce apoptosis and to enhance
radio sensitivity by downregulating PI3K/Akt signalling pathway
(Wen et al, 2001). Tyrphostin AG1024 is a TK inhibitor which
inhibits phosphorylation of IGF1R and MEK and this compound is
also able to induce pRb degradation (Baserga, 2000). In this study,
we investigated in Bcr-Abl expressing cells the effect of this
inhibitor on Akt phosphorylation and its consequences on Bcr-Abl
and the DNA repair protein DNA-PKcs. Furthermore, we
investigated whether Tyrphostin AG1024 induced an antileukae-
mic effect both in vitro and in nude mice as well as the
effectiveness of Tyrphostin AG1024 against STI571 resistant cells.
MATERIALS AND METHODS
Cell culture
UT7 is a pluripotent human erythroleukaemia cell line whose
growth is dependent on GM-CSF (Ahmed et al, 2000). BCR-ABL-
expressing counterparts of this cell line have been obtained by the
use of enforced expression of BCR-ABL by either retroviral
infection or transfection as previously described (Ahmed et al,
2000). UT7-9 cells stably express high levels of the p210 fusion
protein and are GM-CSF-independent for their growth. Murine Ba/
F3 cell line and its BCR-ABL-expressing counterparts have also
been previously described. Human UT7, UT7-9 and murine Ba/F3
and Ba/F3-p210 cells were grown in RPMI 1640 with 10% FCS. A
measure of 10ngml
 1 recombinant human granulocyte-macro-
phage colony-stimulated factor (rhGM-CSF) (R&D Systems, Min-
neapolis, MN, USA) was added to the culture media of UT7 cells and
10% WEHI conditioned medium as a source of interleukin 3 (IL-3)
was added to the culture medium of Ba/F3 cells.
Imatinib mesylate (Gleevec) resistant cells
Cell lines CML blast-crisis K562 and the partially STI571 resistant
K562R cells were kindly provided by Dr Weisberg, Dana Farber
Cancer Institute, Boston, USA and cultured in DMEM medium
supplemented with 10% FCS. These cell lines exhibit Bcr-Abl
overexpression.
Patients derived cells Bone marrow and/or peripheral blood
samples from two patients were obtained after informed consent as
a protocol study sanctioned by the local institutional review board
(IRB). Cells were derived from a splenectomy sample of a Bcr-Abl-
positive CML-blast crisis patient, who relapsed receiving imatinib
mesylate (Gleevec). Mononuclear cells were isolated and used to
purify CD34þ leukaemia blasts, as previously described (Deutsch
et al, 2001).
Assessment of apoptosis after treatment with AG1024
After exposure to Tyrphostin AG1024, apoptotic changes were
detected using fluorescein isothiocyanate (FITC)-annexin V, which
binds to phosphatidylserine exposed on the outer leaflet of
apoptotic cell membranes. Propidium iodide (PI) staining was
used for the discrimination between apoptotic and necrotic cells
among the annexin V1 cells. Cells were washed and resuspended in
490ml binding buffer solution (Annexin V-FITC Kit, Immunotech,
Fullerton, CA, USA). Annexin V-FITC (5ml) and 5ml PI were then
added to the cell suspension for 10min followed by FACS analysis.
Western blot
Cells were washed with cold PBS, and lysed in lysis buffer (50mM
HEPES pH 7.4, 15mM NaCl, 0.1% Tween-20, 10% Glycerol, 2.5mM
EGTA, 1mM EDTA, 1mM phenylmethysulphonyl fluoride, and
inhibitors for proteases). Protein concentration was determined by
using Bradford assay. Equal amounts of proteins were loaded into
wells and separated by 5–12% SDS–PAGE gel. The proteins were
transferred onto nitrocellulose membranes, blocked overnight at
41C in TBS-T solution, containing 5% nonfat milk, and incubated
with primary monoclonal antibodies: ABL (Oncogene, Cambridge,
MA, USA), DNA-PKcs (Neomarker, Fremont, CA, USA), phospho-
Akt (New England Biolab, Beverly, MA, USA), Akt (New England
Biolab), BRCA1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
After washing, the appropriate secondary antibody conjugated to
horseradish peroxydase (Jackson ImmunoResearch Lab, West
Grove, PA, USA) was probed. Membranes were developed using
the enhanced chemiluminescence detection system (Amersham
Biotech Company, Piscataway, NJ, USA). b-Actin (Sigma) was used
to control protein loading. Densitometry analysis of the relative
intensity of spots has been performed in order to quantify the
expression of Bcr-Abl after treatment of both K562 and K562R cells
with Tyrphostin AG1024 using Mac Bas2 software.
Cell proliferation assays
To study the inhibitory effect of Tyrphostin AG1024 on cell growth,
10
6 cells were plated and the different drug concentrations (2, 5, 10
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sand 50nM) were added to the medium. At the indicated time, cell
number and viability were estimated by trypan blue assay.
Clonogenic assays
Both UT7 clones, K562 cells and cells derived from patients were
transplanted in methylcellulose (Stem Cell Technologies) in the
presence of 10ngml
 1 rhGM-SCF for UT7 cells or 10% WEHI for
Ba/F3 cells and graded concentration of Tyrphostin AG1024. The
surviving fraction was determined by measuring the viability of
colony-forming unit compared with the corresponding untreated
controls, data represent the mean of three independent experi-
ments performed in triplicate. Colonies were estimated 10–14 days
after the treatments.
In vivo experiments
Female nude mice (6–8 weeks old) were purchased from Janvier
CERT 53940 Le Genest St Isle, France. Animals used in this study
were maintained in facilities in accordance with current regula-
tions and observing ‘Principles and Guidelines for the Use of
Animals in Research’ Issued by the French government according
to the European community rules. 10
6 Ba/F3-p210 cells in 0.1ml of
were implanted subcutaneously into the right flank of mice and the
animals were randomly assigned to control or treatment group.
Mice were injected i.p. with Tyrphostin AG1024 (30mgi n1 0 0ml)
once per day for 2 weeks in the treatment group and with 100ml
PBS in the control. The mice were inspected daily for the tumour
growth and any other signs of disease or distress. The tumour
volume was calculated from the greatest transverse (width) and
longitudinal (length) diameter of the tumour using the formula:
tumour volume¼length width
2/2.
Statistical analyses
The data are presented as mean values7s.e. The surface areas of
the primary tumours and the body weights were compared by
paired student’s t-test.
RESULTS
Downregulation of BCR-ABL expression by Tyrphostin
AG1024
Immunoblot analysis was used to assess the expression of the
fusion protein Bcr-abl in UT7-9 and Ba/F3-p210 cells after
treatment with Tyrphostin AG1024. As shown in Figure 1,
expression of Bcr-Abl was downregulated by Tyrphostin AG1024
in UT7-9 and Ba/F3-p210 cells.
Tyrphostin AG1024 decreases the expression of Phospho-
Akt (ser473) in BCR-ABL-expressing cells
Further experiments were designed to measure the expression of
phosphorylated forms of AKT. As shown in Figure 1, phospho-Akt
(ser473) levels were downregulated by Tyrphostin AG1024, in a
time-responsive manner but the amount of Akt remained the same
in UT7-9 and Ba/F3-p210 cells. The expression of phospho-Akt
was not influenced by the exposure to Tyrphostin AG1024 in their
parental cells UT7 and Ba/F3-P (data not shown).
Restoration of the DNA-PKcs levels in BCR-ABL-
expressing cells by Tyrphostin AG1024
PI3K and Akt have previously reported to play essential roles in
Bcr-Abl transformation, and our previous work showed that DNA-
P-AKT
AKT
Bcr-Abl
DNA-PKcs
P-AKT
AKT
Bcr-Abl
DNA-PKcs
12 3 12 3
0 6 12 0 6 12
AB
Figure 1 Tyrphostin AG1024 downregulates phospho-Akt, Bcr-Abl and
upregulates DNA-PKcs. (A) UT7-9 and (B) Ba/F3-p210 cells were treated
with Tyrphostin AG1024 2mM, harvested at a definite time interval. Lane 1:
control; lane 2: 6h; lane 3: 12h.
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Figure 2 Clonogenic survival after exposure to Tyrphostin AG1024 of
UT7 and UT7-9 cells (A), Ba/F3 and Ba/F3-p210 (B), respectively.
Experiments were repeated three times, each experiment was triplicated.
Error bars represent the 95% confidence interval.
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sPKcs is downregulated by Bcr-Abl (23). Experiments were
designed to assess whether the expression of DNA-PKcs was
influenced by the TK inhibitor Tyrphostin AG1024. As shown in
Figure 1, treatment with Tyrphostin AG1024 induced an upregula-
tion of DNA-PKcs levels in UT7-9 and Ba/F3-p210 cells (Figure 1).
Decreased clonogenic survival and proliferation of murine
Ba/F3 and human UT7 BCR-ABL-expressing cell lines after
exposure to Tyrphostin AG1024
Clonogenic survival assay showed that Bcr-Abl expressing cells
exhibited higher colony formation inhibition than parental cells
(Figure 2A and B). The effect of Tyrphostin AG1024 on cell
proliferation was evaluated in UT7-9 and Ba/F3-p210 cells.
Proliferation curves showed a dose-dependent inhibition of cell
proliferation after treatment with Tyrphostin AG1024 (in
Figure 3A). The effects of Tyrphostin on cell proliferation and
clonogenic survival was associated with the induction of apoptosis
(Figure 3B).
In vivo inhibition of Bcr-Abl expressing cells growth with
AG1024
In order to complete, our results showing antiproliferation
potential of Tyrphostin AG1024 in Bcr-Abl expressing cells in
vitro. We investigated the antitumour effect of Tyrphostin AG1024
in vivo in nude mice on Ba/F3-p210 xenografts. The tumour
growth was significantly delayed when mice were treated with
Tyrphostin AG1024 (Figure 4).
Efficacy on Tyrphostin AG1024 on Bcr-Abl expressing
STI571 resistant cells
Proliferation curves and colony formation assays for K562 (STI571
sensitive) and K562R (STI571 resistant) cell lines were used to
evaluate the effects of Tyrphostin AG1024 on cell proliferation and
clonogenic survival in Bcr-Abl expressing cells resistant to
STI571(Figure 5). Exposure to AG1024 caused a marked inhibition
of proliferation (Figure 5) and colony formation, this effect was
observed independently of the sensitivity of K562 and K562R cells
to STI571. Interestingly, this effect correlates with a decrease in
Bcr-Abl protein expression in a dose-dependent manner (Figure 6).
Densitometry analysis showed a reduction in Bcr-Abl expression
of, respectively, 38, 43 and 61% in K562R and 41, 59 and 78% in
cells treated with 2, 5 and 10mM Tyrphostin AG1024.
CML cells from STI571 resistant patients are sensitive to
Tyrphostin AG1024
Clonogenic survival with Tyrphostin AG1024 and STI571 was
studied in order to evaluate the effects of this combination on
clonogenic CML cells obtained from patients relapsing after
STI571 treatment. The AG1024 and STI571 were added directly
to the methylcellulose cultures at the time of clonogenic assay and
the results were compared to untreated controls. We observed a
significant inhibition of clonogenic activity with Tyrphostin
AG1024 in two different cases, primary leukaemic cells from two
CML from patients clinically refractory to STI571 treatment
(Figure 7) and in splenocytes derived from one CML patient
refractory to STI571 (Figure 7 and Figure 8 respectively).
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Figure 3 Antiproliferative effect of Tyrphostin AG1024 in UT7-9 and Baf3-p210 cells. (A) Time course of cell proliferation in different concentrations of
Tyrphostin AG1024 in UT7-9 and Baf3-p210 cells, each experiment was carried out triplicate and repeated three times. Error bar shows the mean7s.e. (B)
A time course of apoptosis after exposure to different concentrations of Tyrphostin AG1024 in UT7-9 and Baf3-p210 cells, each experiment was carried out
in triplicate and repeated three times. Error bar shows the mean7s.e.
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sInterestingly, AG1024 concentration of 10 and 50mM are more
effective on CML cells than on normal CD34 cells, suggesting the
existence of a differential effect of Tyrphostin AG1024 (Figure 7).
DISCUSSION
Our results have shown that the proliferation of Bcr-Abl expressing
cells was inhibited after Tyrphostin AG1024 treatment both in
human and murine cell lines in vitro. This growth inhibitory effect
was also effective in vivo, in the murine Ba/F3 Bcr-Abl-p210
leukaemia xenograft model without inducing significant toxicity.
Molecular studies of protein expression showed that exposure to
AG1024 was associated with a decrease in the phosphorylated form
of Akt (Ser 473), which is the main downstream component of the
PI3K/Akt pathway responsible of apoptosis inhibition and cell
proliferation. For the first time to our knowledge we show that the
TK inhibitor, Tyrphostin AG1024, increases the levels of DNA-
PKcs levels with a concomitant decrease in the expression of Bcr-
Abl, suggesting that the use of AG1024 could be beneficial for the
restoration of DNA-PKcs mediated repair in CML cells. This effect
was associated with a concomitant decrease in the expression of
the Bcr-Abl protein in both human and murine UT7 and Ba/F3
models. One of the major characteristics of Ph1þ cells is the
presence of genetic instability, associated with the progression of
the disease from the chronic to the acute phase (Deutsch et al,
2001). During the last years, intense research was investigated to
understand the transformation and malignant progression of
leukaemic cells. Recently, a relationship between the abnormalities
of DNA repair proteins and the oncoprotein Bcr-Abl was suggested
(Deutsch et al, 2001). Indeed, it was established that BCR-ABL
increases the mutation frequency in haematopoietic cells by
inducing a ‘mutator phenotype’. Abnormalities of RAD51 protein
expression have been linked to chemo resistance of CML cells
(Slupianek et al, 2001; Slupianek et al, 2002). The TK dependent
nature of these DNA repair abnormalities suggest that the ability to
restore them by the use of therapeutic agents such as STI571 could
therefore have a therapeutic impact, especially if this could lead to
the retardation of the occurrence of blast crisis. The inhibitory
effect of AG1024 was also observed in STI571 resistant cell lines
(K562R). Exposure to AG1024 in these STI571 resistant cells was
associated with a decrease in Bcr-Abl protein expression both in
K562 and K562R cell lines, but this phenomenon was observed at
higher Tyrphostin AG1024 concentrations than in the UT7 and Ba/
F3 cell lines. Bcr-Abl expressing cells from CML patients refractory
to STI571 treated with Tyrphostin AG1024 also showed a marked
decrease in clonogenic survival. Tyrphostin AG1024 is a TK
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Figure 4 Antitumour effect of Tyrphostin AG1024 Ba/F3-p210 cells.
After injection with 10
6 cells/0.1ml nude mice were injected after 6 days
with PBS 0.1ml (control) or Tyrphostin AG1024 30mg/0.1ml (0.1ml of a
980mM solution) in treatment group i.p. per day for 10 days. The
experiment was repeated two times with five animals in each group. Error
bars represent the mean7s.e. of the ratio.
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Figure 5 Effects of AG1024 exposure in the parental K562 and in the
STI571 resistant K562R cell line. (A) Effects on cell proliferation after 48h
exposure to AG1024 on K562 and K562R cell lines. Experiments were
repeated three times, each experiment was in triplicate. Error bars
represent the 95% confidence interval. (B) Effects of AG1024 on K562 and
K562R colony formation after 10 days culture in a semisolid. Experiments
were repeated three times, each experiment was in triplicate. Error bars
represent the 95% confidence interval.
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Figure 6 Western blot analysis of Bcr-Abl expression in K562 and
K562R cells after exposure to AG1024. b-Actin was used as a loading
control.
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sinhibitor that has originally been reported to be specific for the
IGF1 receptor, it has recently been shown that Tyrphostin AG1024
could inhibit phosphorylation of other TK such as MEK, that is
part of the MAPK signalling pathway. Moreover, exposure to
Tyrphostin AG1024 is also associated to both decrease in the
phosphorylated form and degradation of pRb (vonWillebrand et al,
1998). Recently, Typhostin AG1024 has been reported to induce
apoptosis and to enhance radiosensitivity by downregulating PI3K/
Akt signal pathway (Wen et al, 2001). The relative importance of
IGFR signalling during Bcr-Abl tumorigenic process still has to be
studied. IGF1R is a membrane TK receptor ubiquitously expressed
except on mature B cells and hepatocytes (Valentinis and Baserga,
2001). Insulin-like growth factors (IGFs) have been shown to
potently stimulate cell proliferation and to inhibit cell death
(Komatsu et al, 1997). Several intracellular signalling pathways
have been identified that are activated in response to IGF
stimulation. One of them is the phosphatidylinositol 3-kinase
(PI3K) pathway. In response to IGF stimulation, activated PI3K
converts phosphatidylinositol 4,5-bisphosphate to phosphatidyli-
nositol 3,4,5-trisphosphate, which results in subsequent activation
of the pleckstrin homology domain-containing serine/threonine
kinases PDK1 and Akt. Oncogenes like RAS, SV40 (Sell et al, 1993),
the E7 viral oncoprotein (Steller et al, 1996) as well as TK receptors
EGFR, PDGFR (Coppola et al, 1994) fail to operate cellular
transformation in IGF1R  /  fibroblasts. Whether IGF1R seems to
be required for Bcr-Abl transformation has to be studied. In
conclusion, Tyrphostin AG1024 was found to downregulate the
expression of Bcr-Abl and P-Akt, and to upregulate the DNA-PKcs
protein expression in BCR-ABL expressing cells. In vitro
Tyrphostin AG1024 was found to inhibit cell proliferation and in
vivo to induce tumour growth delay. In addition, an antiproliferate
effect of Tyrphostin AG1024 was observed in haematopoietic cells
resistant to STI571 and in primary CML cells derived from patients
resistant to STI571. This effect of Tyrphostin AG1024 was observed
independently of the mechanism of resistance to STI571, by Bcr-
Abl overexpression or Bcr-Abl gene ATP pocket mutation.
Therefore, this study might provide a rationale basis for a new
strategy to circumvent STI571 resistance by the combined use of
two distinct TK inhibitors in a curative or a preventive setting.
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